The COVID-19 vaccine, BCVax, has been granted by TFDA to proceed to Phase I clinical trial

1.Date of occurrence of the event:2023/06/02 2.New drug name or code:COVID-19 vaccine, BCVax 3.Indication: COVID-19 vaccine, BCVax, is composed of the Delta spike protein with nanoparticle saponins as adjuvant that can induce high-titer antibodies and has neutralization activities on various SARS-CoV-2 variants. As a conventional vaccine, BCVax has the advantages of stability, production maturity, and […]

This article is password protected.

To view the content, please enter your password in the field below